Please login to the form below

Not currently logged in
Email:
Password:

Novartis launches remote clinical trial app

FocalView will allow patients to participate in ophthalmology trials

Novartis

In a bid to step up its digital health game, pharma giant Novartis has launched a remote clinical trial app, which is said to have been designed to ‘modernise’ ophthalmic clinical trials for improved patient participation.

FocalView, a ‘first-of-its-kind’ app made with Apple’s digital platform ResearchKit, allows researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients.

Aiming to enable more sensitive trial endpoints and collect more accurate patient-reported outcomes, Novartis hopes the app may reduce barriers to participation, which will lead to a more nuanced understanding of ophthalmic diseases and potentially accelerate the development of novel treatments.

According to the Swiss pharma group, data captured in traditional ophthalmic clinical trials can be ‘inflexible’ and ‘infrequent’, resulting in challenges for researchers to monitor patients’ disease activity and capture real-world patient experiences.

Bertrand Bodson, chief digital officer for Novartis, said: “Optimising digital technology in research and development, particularly in ophthalmic disease, could have a marked impact on the quality of the data we capture.

“We believe apps like FocalView, which we’ve made freely available to the research community on an open-source platform, can help accelerate the development of treatments and bring them to patients who need them most.”

FocalView will be tested in a prospective, non-interventional study to evaluate the app’s efficacy and usability in assessing visual function.

In the next phase, the app - which is available for download from the App Store in the US - will be validated against traditional visual testing that takes place within conventional clinical settings.

Novartis has confirmed that it will plan to launch in additional markets in the future.

Article by
Gemma Jones

27th April 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics